JP4449746B2 - N−フェニル−(2r,5s)ジメチルピペラジン誘導体 - Google Patents

N−フェニル−(2r,5s)ジメチルピペラジン誘導体 Download PDF

Info

Publication number
JP4449746B2
JP4449746B2 JP2004521198A JP2004521198A JP4449746B2 JP 4449746 B2 JP4449746 B2 JP 4449746B2 JP 2004521198 A JP2004521198 A JP 2004521198A JP 2004521198 A JP2004521198 A JP 2004521198A JP 4449746 B2 JP4449746 B2 JP 4449746B2
Authority
JP
Japan
Prior art keywords
lower alkyl
phenyl
dimethylpiperazine
acid
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004521198A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2004007471A1 (ja
Inventor
伸明 谷口
雅一 今村
昌彦 早川
賢一 川口
武徳 木村
功 木野山
弘行 貝沢
岡田  稔
崇 古谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JPWO2004007471A1 publication Critical patent/JPWO2004007471A1/ja
Application granted granted Critical
Publication of JP4449746B2 publication Critical patent/JP4449746B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004521198A 2002-07-12 2003-07-11 N−フェニル−(2r,5s)ジメチルピペラジン誘導体 Expired - Fee Related JP4449746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002203690 2002-07-12
JP2002203690 2002-07-12
PCT/JP2003/008860 WO2004007471A1 (ja) 2002-07-12 2003-07-11 N−フェニル−(2r,5s)ジメチルピペラジン誘導体

Publications (2)

Publication Number Publication Date
JPWO2004007471A1 JPWO2004007471A1 (ja) 2005-11-17
JP4449746B2 true JP4449746B2 (ja) 2010-04-14

Family

ID=30112682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004521198A Expired - Fee Related JP4449746B2 (ja) 2002-07-12 2003-07-11 N−フェニル−(2r,5s)ジメチルピペラジン誘導体

Country Status (11)

Country Link
US (2) US7297698B2 (enExample)
EP (1) EP1557411B1 (enExample)
JP (1) JP4449746B2 (enExample)
AU (1) AU2003248052A1 (enExample)
CA (1) CA2492138C (enExample)
CY (1) CY1113335T1 (enExample)
DK (1) DK1557411T3 (enExample)
ES (1) ES2393333T3 (enExample)
PT (1) PT1557411E (enExample)
SI (1) SI1557411T1 (enExample)
WO (1) WO2004007471A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE450533T1 (de) * 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
CA2535416A1 (en) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2005108399A1 (ja) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
MX2009000508A (es) * 2006-07-14 2009-01-27 Pfizer Prod Inc Sal tartrato de (7s)-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-me tilpiperazin-1-il]-6,7-dihidro-5h-ciclopenta[b]piridina.
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CN102548991B (zh) 2009-09-24 2015-03-25 霍夫曼-拉罗奇有限公司 作为磷酸二酯酶10a抑制剂的咪唑并吡啶或咪唑并嘧啶衍生物
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス,インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
EP2539706B1 (en) * 2010-02-24 2015-03-04 Research Triangle Institute Arylpiperazine opioid receptor antagonists
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
TW201305130A (zh) * 2010-10-22 2013-02-01 Astellas Pharma Inc 突變雄激素受體拮抗藥
WO2013058361A1 (ja) 2011-10-21 2013-04-25 アステラス製薬株式会社 アンドロゲン受容体拮抗化合物の結晶
US8765767B2 (en) * 2012-03-16 2014-07-01 Bristol-Myers Squibb Company Positive allosteric modulators of mGluR2
PL3231800T3 (pl) * 2014-12-08 2020-04-30 Lsk Nrdo Co., Ltd. Nowa pochodna 4-(arylo) -n-(2-alkoksytieno[3,2-b]pirazyn-3-ylo)-piperazyno-1-karboksyamidu oraz jej działanie antyproliferacyjne
WO2016196955A1 (en) 2015-06-04 2016-12-08 Drexel University Inhibitors of RAD52 Recombination Protein and Methods Using Same
CN105130847A (zh) * 2015-09-10 2015-12-09 成都大学 一种制备高纯邻甲基苯腈及其衍生物的方法
SG11201811225RA (en) 2016-06-22 2019-01-30 Radius Health Inc Ar+ breast cancer treatment methods
SG11202009388XA (en) 2018-03-26 2020-10-29 Basf Se Novel hyperbranched polyesters and their use as wax inhibitor, as pour point depressant, as lubricant or in lubricating oils
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES
AU2022333206A1 (en) 2021-08-27 2024-04-11 Basf Se Aqueous dispersions of paraffin inhibitors
AU2022336800A1 (en) 2021-08-30 2024-04-11 Basf Se Hyperbranched polyesters modified with branched fatty acids and their use as paraffin inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4694004A (en) * 1984-07-09 1987-09-15 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
BR9914018A (pt) * 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
JP2001328938A (ja) * 2000-03-17 2001-11-27 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体を有効成分とする医薬
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
US20050261303A1 (en) 2005-11-24
US7666873B2 (en) 2010-02-23
CA2492138C (en) 2011-01-11
WO2004007471A1 (ja) 2004-01-22
ES2393333T3 (es) 2012-12-20
JPWO2004007471A1 (ja) 2005-11-17
AU2003248052A1 (en) 2004-02-02
US7297698B2 (en) 2007-11-20
EP1557411A1 (en) 2005-07-27
EP1557411B1 (en) 2012-10-17
CA2492138A1 (en) 2004-01-22
CY1113335T1 (el) 2016-06-22
EP1557411A4 (en) 2011-02-23
SI1557411T1 (enExample) 2013-01-31
DK1557411T3 (da) 2012-11-05
US20080214543A1 (en) 2008-09-04
PT1557411E (pt) 2012-11-22

Similar Documents

Publication Publication Date Title
JP4449746B2 (ja) N−フェニル−(2r,5s)ジメチルピペラジン誘導体
KR100660309B1 (ko) 시아노페닐 유도체
JP5916700B2 (ja) アミド化合物、組成物およびそれらの使用
WO1998022432A1 (en) Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
JP5608655B2 (ja) P2x3受容体活性のモジュレーター
JP2001261657A (ja) シアノフェニル誘導体
DE10229777A1 (de) Indolin-Phenylsulfonamid-Derivate
JPWO2000017163A1 (ja) シアノフェニル誘導体
IL216332A (en) An oil extraction method and system splits in situ
JP2002088073A (ja) 抗アンドロゲン剤
CA2610903A1 (en) N-(pyridin-2-yl)-sulfonamide derivatives
EP2447251A1 (en) N-(1-phenyl-2-oxo-3-piperidyl sulphonamide libraries for drug discovery
EP2447249A1 (en) N-phenyl-1-sulfonyl-2-pyrrolidine carboxamide libraries for drug discovery
US20040044041A1 (en) 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
JP2001328938A (ja) シアノフェニル誘導体を有効成分とする医薬
JPWO2019044868A1 (ja) ピリミジン誘導体
US20120157482A1 (en) Compounds and methods
US20120122920A1 (en) Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery
JP2012530097A (ja) 1−(2−アルキル−2,3−ジヒドロ−ベンゾフラン−4−イル)−ピロリジン−3−イルアミンアシル化合物
US20060142268A1 (en) 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivative or salt thereof
AU769186B2 (en) Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
TW202523331A (zh) 作為sstr4激動劑之(2s,5r)-5-(羥甲基)嗎啉-2-甲醯胺
WO2025222049A1 (en) 2-((1-oxo-2,3-dihydro-1h-inden-5-yl)oxy)acetic acid derivatives and related uses
WO2024220487A1 (en) Carbocyclic phenylpyrrolidinone urea fpr2 agonists
CN114075188A (zh) 芳香杂环酰胺类化合物及其制备方法和医药用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100118

R150 Certificate of patent or registration of utility model

Ref document number: 4449746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140205

Year of fee payment: 4

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140205

Year of fee payment: 4

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees